GSK Pharma Plans more Investments to Support Growth

Multinational drug-maker GlaxoSmithKline Pharmaceuticals Ltd expects to see increased expenses towards supporting top-line growth and related promotional efforts in the months ahead. The company has seen a 28 percent growth in net profit before exceptional items, and to support this and the top-line growth, the company will see more investments in supportive field-force and promotional efforts. GSK Pharma has several products lined up for the year, including vaccines, Infanrix-Hexa (a six-component vaccine) and pneumococcal vaccine Synflorix, besides a couple of cancer drugs and a blood-platelet boosting drug. GSK was present in the derma market, with about 60 per cent coverage. But the global acquisition of Stiefel Laboratories Inc translated into giving it over 90 per cent presence in the dermatology segment, company top-brass said.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video